Application of “B+1” heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccines
Saved in:
| Main Authors: | Zezhong Liu, Lu Lu, Shibo Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2192817 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
by: Leiping Zeng, et al.
Published: (2022-05-01) -
Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants
by: Ji Hyang Jeon, et al.
Published: (2025-05-01) -
Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
by: Jialu Zhang, et al.
Published: (2021-01-01) -
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice
by: Xiaoming Liang, et al.
Published: (2025-01-01) -
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection
by: Rui Qiao, et al.
Published: (2025-06-01)